Two-Year ADAPT-DES Data Examine Relationship of IVUS Guidance on DES Outcomes

 

November 16, 2018—Two-year follow-up data from the large-scale ADAPT-DES study assessing dual-antiplatelet therapy with drug-eluting stents (DESs) implanted with intravenous ultrasound (IVUS) guidance were published by Akiko Maehara, MD, et al online ahead of print in Circulation: Cardiovascular Interventions. The study had previously shown that IVUS-guided DES implantation was associated with a reduction in 1-year rates of stent thrombosis, myocardial infarction (MI), and major adverse cardiac events (MACE; defined as cardiac death, MI, or stent thrombosis) compared with angiography guidance alone.

The prospective, multicenter, nonrandomized all-comers study of 8,582 consecutive patients at 11 sites in the United States and Germany was designed to determine the frequency, timing, and correlates of adverse events after DES.

The investigators now sought to determine whether the benefits of IVUS guidance were maintained, reduced, or increased at 2 years.

As summarized in Circulation: Cardiovascular Interventions, the investigators performed a propensity-adjusted multivariable analysis to examine the impact of IVUS guidance on 2-year outcomes.

The investigators reported that IVUS guidance (n = 3,361; 39%) compared with angiography guidance (n = 5,221; 61%) was associated with reduced 2-year adjudicated rates of the following:

  • MACE (4.9% vs 7.5%; adjusted hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.59–0.89; P = .003),
  • Definite/probable stent thrombosis (0.55% vs 1.16%; adjusted HR, 0.4; 95% CI, 0.22–0.73; P = .003)
  • MI (3.5% vs 5.6%; adjusted HR, 0.65; 95% CI, 0.51–0.83; P = .0006).

By landmark analysis, IVUS guidance compared with angiography guidance was also associated with significantly reduced rates of MACE, MI, stent thrombosis, and clinically driven target lesion revascularization between 1 and 2 years after DES implantation. The average number needed to treat with IVUS guidance to prevent one MACE was reduced from 64 (42–137) at 1 year to 41 (29–69) at 2 years.

In ADAPT-DES, the early improvement in event-free survival after DES implantation with IVUS guidance compared with angiography guidance was further increased with the longer-term follow-up to 2 years, concluded the investigators in Circulation: Cardiovascular Interventions.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.